Evidence map›Paper›PMID 40832726›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

SCORCH2: A Generalized Heterogeneous Consensus Model for High-Enrichment Interaction-Based Virtual Screening.

Lin Chen, Vincent Blay, Pedro J Ballester, Douglas R Houston

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Lin ChenInstitute for Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh, EH9 3BF, UK.ORCID https://orcid.org/0000-0002-8480-6559
Vincent BlayDepartment of Microbiology and Environmental Toxicology, University of California at Santa Cruz, Santa Cruz, California, 95064, USA.ORCID https://orcid.org/0000-0001-9602-2375
Pedro J BallesterDepartment of Bioengineering, Imperial College London, London, SW7 2AZ, UK.ORCID https://orcid.org/0000-0002-4078-743X
Douglas R HoustonInstitute for Quantitative Biology, Biochemistry and Biotechnology, University of Edinburgh, Edinburgh, EH9 3BF, UK.ORCID https://orcid.org/0000-0002-3469-1546

Funding

Medical Research Council MR/Y013131/1Rosetrees TrustThe Darwin Trust of Edinburgh
6 · The paper itself

Abstract

The discovery of effective therapeutics remains a complex, costly, and time-consuming endeavor, characterized by high failure rates and significant resource investments. A central bottleneck in early-stage drug discovery is identifying suitable hit compounds with moderate affinity for known biological targets. Although advancements occur, current in silico virtual screening methods are subject to limitations, including model overfitting, data bias, and constrained interpretability in their predictive processes. In this study, we present SCORCH2, a machine learning-based framework designed to simultaneously enhance the performance and interpretability of virtual screening by leveraging interaction features. Comparing with its predecessor SCORCH, SCORCH2 exhibits superior predictive accuracy and generalizability across a wide range of biological targets. Importantly, SCORCH2 demonstrates robust hit identification capabilities on previously unseen targets, indicating strong transferability. Furthermore, SCORCH2 obviates the need for meticulous docking pose selection, streamlining the screening process. These advances highlight the potential of SCORCH2 as a valuable tool in accelerating drug discovery campaigns.

Indexed as

Drug DiscoveryMachine LearningComputer SimulationDrug Evaluation, PreclinicalHumansMolecular Docking Simulationdrug discoverymachine learningmolecular interactionvirtual screening

Identifiers

PMID40832726
PMCPMC12622527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.